NEO NeoGenomics Inc
Company Analysis
Latest News
🔴 NeoGenomics is trading 5.5% down today as investors reposition ahead of Q2 earnings
NeoGenomics is trading 5.5% down at $13.13 as investors reposition ahead of its Q2 2026 earnings report scheduled for July 28, 2026. • The stock has shown...
NeoGenomics Inc Q2 2026 Earnings Preview: What Analysts Expect on July 28, 2026
NeoGenomics is expected to report Q2 2026 revenue of approximately $196.99 million and a consensus loss of $0.06 per share, with the current stock price of...
NeoGenomics Reaches $9.8M Settlement with U.S. DOJ to Resolve Investigation
NeoGenomics has finalized a civil settlement with the U.S. Department of Justice (DOJ) to resolve an investigation into the compliance of certain consulting...
🔴 NeoGenomics is trading 5% down today on profit-taking after FDA-approved diagnostic launch
NeoGenomics is trading 5% down at $13.99 as shares pull back following the initial market reaction to its latest FDA approval. • The company launched PTEN IHC...
NeoGenomics launches first FDA-approved prostate diagnostic for AstraZeneca’s TRUQAP
NeoGenomics, Inc. launched PTEN IHC CDx, the first FDA-approved immunohistochemistry companion diagnostic for prostate adenocarcinoma. The test identifies PTEN...
🔴 NEO is trading 5.2% down today on profit-taking and technical pressure
NEO is trading 5.2% down at $14.38 as profit-taking and technical pressure mount following a strong multi-week uptrend. • There are no fresh company-specific...
NeoGenomics Completes Upsized $316.25M Convertible Senior Notes Offering Due 2032
NeoGenomics has successfully completed an upsized private offering of convertible senior notes, raising a total of $316.25 million in aggregate principal. The...
NeoGenomics Announces Pricing of $275M Convertible Senior Notes Offering Due 2032
NeoGenomics announced the pricing of a private offering of $275 million in aggregate principal amount of 0.75% convertible senior notes due 2032. The company...